A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the lntraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Rectum or Pancreas

Trial Profile

A Phase I Study Assessing the Safety and Performance of SGM-101, a Fluorochrome-Labeled Anti-Carcinoembryonic Antigen Monoclonal Antibody for the lntraoperative Detection of Neoplastic Lesions in Patients with Cancer of the Rectum or Pancreas

Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs SGM 101 (Primary)
  • Indications Pancreatic cancer; Rectal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top